Swedish pharma company secures NHS reimbursement for liquid form of phenylbutyrate

Swedish Orphan Biovitrum (Sobi) — a pharmaceutical company that specialises in rare diseases — has secured NHS England reimbursement for its medicine for the management of urea cycle disorders (UCDs), Ravicti (glycerol phenylbutyrate). Read more

23 Aug 2018 12:28 News